TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12907822

Group type: EXPERIMENTAL
Intervention: heparin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: therapeutic thrombolysis (tPA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: hypothermia
Number of subjects: 50

Group type: COMPARATOR
Intervention: healthy persons
Number of subjects: 50
Study: 10976988

Group type: EXPERIMENTAL
Intervention: Congenital hip dysplasia (CHD) patients
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (no CHD)
Number of subjects: 240
Study: 8862101

Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 to 40 mg once daily
Number of subjects: 4444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study: 1506543

Group type: EXPERIMENTAL
Intervention: Stress management programme as part of an overall fitness programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost evaluation of the stress management programme
Number of subjects: 0
Study: 6131914

Group type: EXPERIMENTAL
Intervention: anti-H1 plus anti-H2 (cimetidine, 300 mg t.i.d.)
Number of subjects: 23

Group type: COMPARATOR
Intervention: anti-H1 plus placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: anti-H1 alone
Number of subjects: 23
Study: 28974127

Group type: EXPERIMENTAL
Intervention: Atomoxetine for 6 weeks
Number of subjects: 52
Study: 28449710

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES) 130/0.4, 20 mL·kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5% Human Albumin (HA), 20 mL·kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both HES and HA
Number of subjects: 60
Study: 25767382

Group type: EXPERIMENTAL
Intervention: Mindful meditation intervention (8-week program)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mindful meditation intervention (8-week program) with 6 or more classes
Number of subjects: 41
Study: 23765203

Group type: EXPERIMENTAL
Intervention: Discontinuation of dietary MSG and aspartame (n = 36)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Waiting list (n = 36)
Number of subjects: 72
Study: 21926614

Group type: EXPERIMENTAL
Intervention: Early feeding (enteral nutrition within 24 hrs of admission)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Delayed feeding (no enteral nutrition during the first 4 days of admission)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Delayed feeding
Number of subjects: 28
Study: 20698174

Group type: EXPERIMENTAL
Intervention: Thermography assessment in SLE patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Thermography assessment in healthy controls
Number of subjects: 34
Study: 17563658

Group type: EXPERIMENTAL
Intervention: New TEAM program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Old TEAM program
Number of subjects: 0
Study: 15857746

Group type: EXPERIMENTAL
Intervention: Regular examinations in participating patients (16 patients)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-participating patients (49 patients)
Number of subjects: 65
Study: 11922851

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) at sensory threshold
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) at 1.5 times motor threshold
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES) at varying sites
Number of subjects: 32
Study: 11783154

Group type: EXPERIMENTAL
Intervention: Tongxinluo capsule (TXLC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Isosorbide mononitrate
Number of subjects: 64
Study: 7594246

Group type: EXPERIMENTAL
Intervention: Fiber supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 2148882

Group type: EXPERIMENTAL
Intervention: Subcutaneous bolus injection of GM-CSF (0.3-30 micrograms/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of GM-CSF (0.3-30 micrograms/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of GM-CSF (0.3-30 micrograms/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All methods of administration (subcutaneous bolus, intravenous bolus, intravenous infusion)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of GM-CSF at doses below 3 micrograms/kg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All methods of administration
Number of subjects: 33
Study: 106264

Group type: EXPERIMENTAL
Intervention: 3 X 50 mg bezafibrate daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3 X 100 mg bezafibrate daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3 X 150 mg bezafibrate daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3 X 200 mg bezafibrate daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 600 mg bezafibrate daily (optimal dose)
Number of subjects: 24
Study: 31455566

Group type: EXPERIMENTAL
Intervention: Feedback Guide intervention
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 29
Study: 30563932

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg daily for 3 days, then twice daily for 1 to 5 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 88
Study: 27654012

Group type: EXPERIMENTAL
Intervention: Intravesical hyaluronic acid (HA) and chondroitin sulfate (CS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Dimethyl sulfoxide (DMSO)
Number of subjects: 110
Study: 25945555

Group type: EXPERIMENTAL
Intervention: Oxylator-aided laryngeal tube ventilation (OLTV)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mouth-to-mouth ventilation (MMV)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oxylator-aided mask ventilation (OMV)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: No ventilation (NV)
Number of subjects: 17
Study: 24063678

Group type: EXPERIMENTAL
Intervention: Cardio Zip shoe
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All shoes at 8-weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Other three shoes
Number of subjects: 36
Study: 21318314

Group type: EXPERIMENTAL
Intervention: Hopping at 1.5 Hz
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hopping at 2.2 Hz
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hopping at 3.0 Hz
Number of subjects: 14
Study: 19479614

Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (RT) after induction chemotherapy (CT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone
Number of subjects: 54
Study: 18246732

Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Band ligation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study: 14684415

Group type: EXPERIMENTAL
Intervention: Transfusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study: 11485506

Group type: EXPERIMENTAL
Intervention: Alosetron hydrochloride 1 mg twice daily for 12 weeks
Number of subjects: 626

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 626
Study: 9740096

Group type: EXPERIMENTAL
Intervention: Magnetic resonance (MR) bolus tracking
Number of subjects: 6

Group type: COMPARATOR
Intervention: [(15)O]H2O positron emission tomography (PET)
Number of subjects: 6
Study: 8035989

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 0
Study: 2692178

Group type: EXPERIMENTAL
Intervention: Oral salbutamol 4 mg t.d.s.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol infused until maternal heart rate rose above 100 bpm for 30 mins
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no tocolysis)
Number of subjects: 90
Study: 1146460

Group type: EXPERIMENTAL
Intervention: Various therapeutic protocols
Number of subjects: 0
Study: 31427745

Group type: EXPERIMENTAL
Intervention: TIMOLOL nasal spray (0.5%) administered as one spray (50 µL) in each nostril twice a day for 28 consecutive days.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo nasal spray administered as one spray (50 µL) in each nostril twice a day for 28 consecutive days.
Number of subjects: 58
Study: 27889661

Group type: EXPERIMENTAL
Intervention: Screening with PSA threshold of 3 ng/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening with PSA threshold of 4 ng/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening interval of two years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening interval of four years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (Finland)
Number of subjects: 0
Study: 26272447

Group type: EXPERIMENTAL
Intervention: Massage therapy with lavender oil (2 consecutive cycles of effleurage massage)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Isometric exercises (8 weeks)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 102
Study: 24156091

Group type: EXPERIMENTAL
Intervention: Nutritional supplement taken each dialysis session (drink or pudding style)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Number of subjects: 30
Study: 22205554

Group type: EXPERIMENTAL
Intervention: MCT/LCT fat infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fish oil‐based (ω‐3) fat infusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sepsis group 1 (S1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sepsis group 2 (S2)
Number of subjects: 40
Study: 19078948

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 595
Study: 16918949

Group type: EXPERIMENTAL
Intervention: GH treatment (1.3, 2.0 and 2.7 mg/m2/day)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: GH treatment (2.7 mg/m2/day)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 65
Study: 12950901

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg twice a day for 2 days (days 1 and 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg twice a day for 8 days (days 1 and 8)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Itraconazole 200 mg single dose (day 1)
Number of subjects: 45
Study: 10872186

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (children without rhGH treatment)
Number of subjects: 10
Study: 9166391

Group type: EXPERIMENTAL
Intervention: Ipriflavone (200 mg t.i.d)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Ipriflavone
Number of subjects: 255
Study: 1545589

Group type: EXPERIMENTAL
Intervention: Eder-Puestow dilators
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Balloon dilators
Number of subjects: 123
Study: 4074623

Group type: EXPERIMENTAL
Intervention: +sotalol (0.125 mg kg‐1 to 2.0 mg kg‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: (+/‐)‐sotalol
Number of subjects: 6
Study: 31352900

Group type: EXPERIMENTAL
Intervention: Dark-blood LGE
Number of subjects: 300

Group type: COMPARATOR
Intervention: Bright-blood LGE
Number of subjects: 300
Study: 29718811

Group type: EXPERIMENTAL
Intervention: Total offloading foot brace
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard therapy (control)
Number of subjects: 17
Study: 26519439

Group type: EXPERIMENTAL
Intervention: MMFS-01
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 23865441

Group type: EXPERIMENTAL
Intervention: LOS + HCTZ (50 mg/day losartan + 12.5 mg/day hydrochlorothiazide)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: TEL + HCTZ (40 mg/day telmisartan + 12.5 mg/day hydrochlorothiazide)
Number of subjects: 59
Study: 23514683

Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Compomer
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Composite resin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dual curing resin cement
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (intact tooth)
Number of subjects: 150
Study: 20093961

Group type: EXPERIMENTAL
Intervention: Moderate intensity (65% 1 repetition maximum [1RM])
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High intensity (85% 1RM)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Multiple set protocols
Number of subjects: 17

Group type: COMPARATOR
Intervention: Single set protocols
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-intensity, multiple set bout
Number of subjects: 17
Study: 18713908

Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation (ASV)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Pressure-controlled/pressure-support MV
Number of subjects: 346
Study: 11386625

Group type: EXPERIMENTAL
Intervention: Equity-focused screening test offered to 100% of the Medicaid population
Number of subjects: 0

Group type: COMPARATOR
Intervention: Equity-focused screening test offered to half of the Medicaid population
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Order of scenarios presented to subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broad framing of population for screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Narrow framing of population for screening
Number of subjects: 0
Study: 9473250

Group type: EXPERIMENTAL
Intervention: HLA‐identical sibling transplants
Number of subjects: 744

Group type: COMPARATOR
Intervention: Hydroxyurea or interferon
Number of subjects: 744
Study: 7846193

Group type: EXPERIMENTAL
Intervention: Imipramine (mean dose 75 mg daily) plus mianserin (mean dose 25 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Desipramine (mean dose 66 mg daily) plus mianserin (mean dose 27 mg daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Assessment of side-effects using the UKU scale
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Melancholia Scale (MES)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hamilton Depression Scale (HAMD)
Number of subjects: 20
Study: 3362395

Group type: EXPERIMENTAL
Intervention: Anterior resection plus intracolonic by-pass (ARIB)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Anterior resection (AR)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Anterior resection (ARIB)
Number of subjects: 19
Study: 31172644

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg oral administration)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dinoprostone (intravaginal instillation)
Number of subjects: 100
Study: 29103416

Group type: EXPERIMENTAL
Intervention: Phlai capsules 100 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phlai capsules 200 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 20
Study: 25882986

Group type: EXPERIMENTAL
Intervention: Pazopanib plus weekly paclitaxel (800 mg daily + 80 mg/m² weekly)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Weekly paclitaxel alone (80 mg/m² weekly)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pazopanib plus weekly paclitaxel
Number of subjects: 74
Study: 24306019

Group type: EXPERIMENTAL
Intervention: Traditional remediation program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fitness for Life program (pedometer-based program with individual counseling and follow-up calls)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fitness for Life program
Number of subjects: 0
Study: 22813409

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol (60,000 units/week) and calcium carbonate (1g/day) along with anti-tubercular treatment (ATT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 45
Study: 19401624

Group type: EXPERIMENTAL
Intervention: Functional Relaxation (FR)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both FR and GI (FR/GI)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo Relaxation Technique (Control Intervention)
Number of subjects: 64
Study: 16395307

Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg pretreatment with lower subperceptual ketamine dose (0.081 mg/kg bolus, 0.4 mg/kg/h infusion)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Higher perception-altering ketamine dose (0.23 mg/kg bolus, 0.58 mg/kg infusion)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Lower subperceptual ketamine dose
Number of subjects: 55

Group type: COMPARATOR
Intervention: Higher ketamine dose
Number of subjects: 55

Group type: COMPARATOR
Intervention: Naltrexone
Number of subjects: 55
Study: 15005907

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psoriasis symptom management programme (PSMP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard pharmacological care
Number of subjects: 40
Study: 10890543

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 50
Study: 9059198

Group type: EXPERIMENTAL
Intervention: Alfentanil (group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fentanyl (group F)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sufentanil (group S)
Number of subjects: 28
Study: 8370859

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention placebo (nonspecific self-monitoring)
Number of subjects: 0
Study: 31629207

Group type: EXPERIMENTAL
Intervention: Comprehensive nurse-led discharge intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (standard discharge process)
Number of subjects: 200
Study: 27992944

Group type: EXPERIMENTAL
Intervention: Google Glass intervention used by otolaryngology residents
Number of subjects: 95
Study: 26703286

Group type: EXPERIMENTAL
Intervention: Multifocal add-on IOL (Diff-sPB) in the sulcus
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional multifocal IOL (Diffractiva-s) in the capsular bag
Number of subjects: 26
Study: 23439461

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (n = 9)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Normothermia (n = 10)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (diagnostic lumbar puncture, n = 5)
Number of subjects: 56
Study: 20431933

Group type: EXPERIMENTAL
Intervention: Inpatient HIV counseling and testing (HCT)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Outpatient HIV counseling and testing (HCT) 1 week post-discharge
Number of subjects: 500
Study: 19222770

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative local anesthetic mixture (10 mL 2% lidocaine added to 10 mL 0.5% bupivacaine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Preoperative saline and postoperative local anesthetic mixture (10 mL 2% lidocaine added to 10 mL 0.5% bupivacaine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Preoperative local anesthetic mixture and postoperative saline
Number of subjects: 80

Group type: COMPARATOR
Intervention: Preoperative and postoperative 0.9% saline
Number of subjects: 80
Study: 16508385

Group type: COMPARATOR
Intervention: Placebo for 4 days before surgery and on the morning of surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Placebo for 4 days before surgery and oral rofecoxib 50 mg on the morning of surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral rofecoxib 50 mg for 4 days before surgery and the morning of surgery
Number of subjects: 30
Study: 15266820

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 999

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 999
Study: 11524352

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine (15 mL, 75 mg)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine with 1:400,000 epinephrine
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine with 1:200,000 epinephrine
Number of subjects: 117
Study: 9236446

Group type: EXPERIMENTAL
Intervention: Sidestream smoke exposure
Number of subjects: 17

Group type: COMPARATOR
Intervention: Vehicle (air) inhalation
Number of subjects: 17
Study: 8103703

Group type: EXPERIMENTAL
Intervention: Cetirizine (15 mg single dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cetirizine (15 mg twice daily for 1 week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (after single dose PAF challenge)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (after 1 week treatment)
Number of subjects: 10
Study: 3092699

Group type: EXPERIMENTAL
Intervention: 0.15‐0.2 mg/kg nalbuphine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.75‐1.0 mg/kg tramadol
Number of subjects: 60
Study: 30350758

Group type: EXPERIMENTAL
Intervention: Direct Anterior (DA) approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional Direct Lateral (DL) approach
Number of subjects: 100
Study: 27545351

Group type: EXPERIMENTAL
Intervention: 3-day interdialytic interval
Number of subjects: 41
Study: 24886353

Group type: EXPERIMENTAL
Intervention: ThinkingFit intervention (complex multimodal activity programme)
Number of subjects: 67
Study: 22246982

Group type: EXPERIMENTAL
Intervention: 15 mJ double pulse CO(2) laser
Number of subjects: 12

Group type: COMPARATOR
Intervention: 30 mJ single pulse CO(2) laser
Number of subjects: 12
Study: 20299995

Group type: EXPERIMENTAL
Intervention: Ultrasound out-of-plane approach
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ultrasound in-plane approach
Number of subjects: 120

Group type: COMPARATOR
Intervention: Neurostimulation
Number of subjects: 120
Study: 18420265

Group type: EXPERIMENTAL
Intervention: Micro-push-out test (Mpo)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hourglass-shaped microtensile test (Mh)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Push-out test
Number of subjects: 30
Study: 16896732

Group type: EXPERIMENTAL
Intervention: E40% (40% of 1 RM)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: E80% (80% of 1 RM)
Number of subjects: 17

Group type: COMPARATOR
Intervention: C (40 min of rest)
Number of subjects: 17
Study: 12508294

Group type: EXPERIMENTAL
Intervention: Ulnar segmental nerve conduction studies (SgNCS) at 2‐cm intervals
Number of subjects: 21

Group type: COMPARATOR
Intervention: Routine ulnar motor and sensory studies
Number of subjects: 21